Home > Insider Trading > Filing (0001209191-20-021160)

Filing Details

Accession Number:: 0001209191-20-021160
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-25 17:28:54
Reporting Period:: 2020-03-23

Accepted Time:: 2020-03-25 17:28:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1694187	Neon Therapeutics Inc.	NTGN	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1326628	Len Blavatnik	C/O Access Industries, Inc. 40 West 57Th Street, 28Th Floor New York NY 10019	No	No	No	Yes
1391297	Access Industries Holdings Llc	40 West 57Th St, 28Th Fl New York NY 10019	No	No	Yes	No
1468950	Ltd. Industries Biotechnology Clal	3 Azrieli Center Triangle Tower 45 Floor Tel Aviv L3 67023	No	No	No	Yes
1508226	Access Industries Management, Llc	C/O Access Industries, Inc. 40 West 57Th Street, 28Th Floor New York NY 10019	No	No	No	Yes
1508227	Access Industries, Llc	C/O Access Industries, Inc. 40 West 57Th Street, 28Th Floor New York NY 10019	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-03-24	117,400	$2.20	1,896,176	No	4	S	Direct
Common Stock	Disposition	2020-03-24	84,286	$2.19	856,304	No	4	S	Indirect	By corporation
Common Stock	Disposition	2020-03-23	50,358	$2.17	940,590	No	4	S	Indirect	By corporation

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	By corporation
No	4	S	Indirect	By corporation

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.20 to $2.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The securities reported are held directly by Access Industries Holdings LLC ("AIH") and may be deemed to be beneficially owned by Access Industries, LLC ("Access LLC"), Access Industries Management, LLC ("Management LLC") and Len Blavatnik, because Access LLC holds a majority of the outstanding voting interests in AIH, Management LLC controls Access LLC and AIH, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than AIH) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than AIH) is the beneficial owner of such securities for any purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.19 to $2.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The securities reported are held directly by Clal Biotechnology Industries Ltd. ("CBI"). AIH, Access LLC, Management LLC and Len Blavatnik may be deemed to beneficially own the securities held directly by CBI because Clal Industries Ltd. ("CI") is the controlling shareholder of CBI, AIH controls CI, Access LLC holds a majority of the outstanding interests in AIH, Management LLC controls Access LLC, and Len Blavatnik controls Management LLC and Access LLC. Each of the reporting persons (other than CBI) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, if any, and this Form shall not be construed as an admission that any such reporting person (other than CBI) is the beneficial owner of such securities for any purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.16 to $2.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.